最新数据显示，以心脑血管疾病、癌症、糖尿病、慢性呼吸系统疾病四大疾病为代表的重大慢性 病，已经成为威胁我国居民健康的最主要疾病。慢性病死亡人数占总死亡数的比例超过80%，60岁及以 上老年人慢性病患病率超过78%。 值得一提的是，中医药在慢性病防治中正发挥着独特优势。"治未病"的理念与现代预防医学不谋而 合。从膏方调理到八段锦锻炼，越来越多的慢性病患者在中医药的帮助下，改善了症状，提高了生活质 量。 ——"筛"于早期，推动防治关口前移。 从完善慢性病监测体系，到推进慢性病分级诊疗，再到建成多个国家慢性病综合防控示范区……据 监测，我国重大慢性病过早死亡率从2015年的18.5%下降至2023年的15.0%。 这四大健康"杀手"并非孤立存在。高血压往往是心梗、脑卒中的"导火索"；肥胖是糖尿病和多种癌 症的共同诱因；吸烟不仅是肺癌的元凶，也是慢阻肺病的"助推器"……这种相互关联的特点，决定了慢 性病防治不能"头疼医头、脚疼医脚"。 国家卫生健康委有关负责人表示，下一步，要以国家慢性病综合防控示范区建设为抓手，进一步落 实政府主导、多部门协同、全社会参与的机制，进一步加强多病共防、医防融合、综合防控的措施。 当前， ...

Key Takeaways CHE shares sank 15% after Q4 EPS and revenues missed estimates, with margins contracting.Chemed's VITAS revenues rose 1.9%, while Roto-Rooter sales fell 3.7% y/y.CHE's gross margin shrank 181 bps and the 2026 EPS outlook of $23.25-$24.25 fell short of estimates. Chemed Corporation (CHE) reported fourth-quarter 2025 adjusted earnings per share (EPS) of $6.42, which fell 6% year over year. The figure missed the Zacks Consensus Estimate by 8.55%.The company’s GAAP EPS was $6.02, up 2% from last y ...

Core Insights - BrightSpring Health Services, Inc. (BTSG) reported quarterly earnings of $0.33 per share, missing the Zacks Consensus Estimate of $0.34 per share, but showing an increase from $0.22 per share a year ago, resulting in an earnings surprise of -1.49% [1] - The company achieved revenues of $3.55 billion for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 5.85% and up from $3.05 billion year-over-year [2] - BrightSpring Health Services has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates four times in the same period [2] Earnings Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the company's earnings outlook [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $3.31 billion, and for the current fiscal year, it is $1.37 on revenues of $14.56 billion [7] Industry Context - The Medical Services industry, to which BrightSpring belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact BrightSpring's stock performance [5][6]

PACS Group, Inc. (PACS) came out with quarterly earnings of $0.43 per share, missing the Zacks Consensus Estimate of $0.48 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.47%. A quarter ago, it was expected that this company would post earnings of $0.46 per share when it actually produced earnings of $0.32, delivering a surprise of -30.43%.Over the last four quarters, the compan ...

Alignment Healthcare (ALHC) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.16 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +67.04%. A quarter ago, it was expected that this Medicare Advantage insurer would post a loss of $0.07 per share when it actually produced earnings of $0.02, delivering a surprise of +128.57%.Over the last four qua ...

Solventum (SOLV) came out with quarterly earnings of $1.57 per share, beating the Zacks Consensus Estimate of $1.5 per share. This compares to earnings of $1.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +4.67%. A quarter ago, it was expected that this health care company would post earnings of $1.43 per share when it actually produced earnings of $1.5, delivering a surprise of +4.9%.Over the last four quarters, the compa ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores. ...

本次合作将Mirxes的突破性miRNA及多组学技术、核心产品(GASTROClear及LUNGClear)及其日益成熟 的临床管线(涵盖结直肠癌、肝癌、乳癌的成熟临床管线及CADENCE多癌种检测)与Apollo丰富的临床 专业知识、全国医院网络及社区医疗服务的提供能力结合，以实现宏伟的愿景：及早检测癌症、于可治 愈时介入及改变数百万患者的治疗结果。 本次合作旨在规模化地实现该等解决方案的商业化及市场采用，继而扩大区域内早期疾病筛检的覆盖范 围。董事会亦认为，与Apollo的建议战略合作属重大协同机会，符合本集团的长远战略目标。合作旨在 凭借Apollo的广大医院网络及庞大患者群，促进本集团癌症早期检测解决方案的广泛使用，继而弥补印 度医疗体系中的现存不足，尤其是在早期检测及疾病筛查方面。董事会进一步认为，是次合作可为本集 团未来在印度扩充业务的延展平台，有助更早进行临床干预，并改善患者的治疗效果。 MIRXES-B(02629)发布公告，本公司已与Apollo Health and Lifestyle Limited(AHLL，为Apollo Hospitals Enterprise Limited(Ap ...

本公告乃由Mirxes Holding Company Limited（「本公司」，連同其附屬公司統稱「本 集團」）自願刊發，旨在知會本公司股東及潛在投資者有關本集團的最新業務 發展。 諒解備忘錄 本公司董事（「董事」）會（「董事會」）宣佈，本公司已與Apollo Health and Lifestyle Limited（「AHLL」，為Apollo Hospitals Enterprise Limited（「Apollo」）的全資附屬公 司）訂立諒解備忘錄（「諒解備忘錄」）以尋求進行戰略合作，從而於印度及鄰近 國家共同開發及商業化先進的癌症早期檢測解決方案。待達成協定目標及獲 各自董事會批准後，預期將會於印度創立一家合營公司，根據本公司及Apollo 將注入的知識產權、臨床管線、研發、臨床試驗基礎設施及商業渠道，其股權 價值將不少於50百萬美元。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limite ...

Key Takeaways ACHC beat Q4 earnings and revenue estimates as admissions and patient days increased.ACHC's same-facility revenues rose 4.4% on 3.1% higher patient days and 2.5% admissions growth.ACHC sees 2026 revenues of $3.37B-$3.45B and adjusted EBITDA of $575M-$610M.Acadia Healthcare Company, Inc. (ACHC) reported adjusted fourth-quarter earnings of 7 cents per share, which beat the Zacks Consensus Estimate of 3 cents. However, the bottom line declined 89% year over year.Total revenues increased 6.1% year ...